Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L.sup.1 and L.sup.2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).

##STR00001##

The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology:

##STR00001## in Chemical Formula I, A is CH.sub.2 or O; a is 0 or an integer of 1 to 10; X is CH.sub.2 or CONH; Y is CH.sub.2 or

##STR00002##

and Z is the biomolecule, the fluorescent dye or the nanoparticle compound,

##STR00003## in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH.sub.2 or CONH; and Q is or

##STR00004## M, M and M in Q are radioisotopes.

The present invention relates to a pigment-coupled mannosyl serum albumin complex and a lymph node-probing composition comprising the same. More particularly, when administered to mice, a pigment-coupled mannosyl serum albumin complex can be observed with the naked eye to exist in a condense state for a long period of time in the inguinal lymph node. Thus, the complex and a composition comprising the same can be useful for probing lymph nodes.

A method for synthesis and purification of radiolabeled macroaggregated human serum albumin (MAA) to form a bulk solution injectable to a patient includes: providing a radiometal in a generator, the radiometal being a generator eluate; synthesizing the radiolabeled MAA in a reactor with MAA particles from a commercially available labeling kit for 99mTc and the generator eluate so as to provide synthesized radiolabeled MAA particles; passing the synthesized radiolabeled MAA particles on a syringe filter membrane having a membrane composition, diameter, and pore size for trapping the radiolabeled MAA particles as trapped radiolabeled MAA particles and not retaining impurities from a bulk solution, the impurities including free radioactive metal isotopes, parent radioactive metal breakthrough, and stannous chloride present in the MAA labeling kit for 99mTc; and untrapping the trapped radiolabeled MAA particles from the syringe filter using a saline or buffered solution passing through the syringe filter.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.

Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.

Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.

The present invention relates to an injectable composition for labeling a lesion and a method for providing information on the position of the lesion using the injectable composition. More specifically, the injectable composition for labeling a lesion according to the present invention can include a second composition comprising a biocompatible viscous material in a first composition comprising a complex containing an active ingredient to resolve a problem of rapid settling of the complex. Additionally, in particular, the injection composition for labeling a lesion according to the present invention can have an effect of allowing a predetermined amount of the complex to be injected by resolving the problem of rapid settling of the complex during preparation of the injection, allowing a certain amount of the complex to be injected, and an effect of enabling convenient and stable use thereof for clinical purposes by resolving the problems of injecting an excessive amount of the complex and the quick spread thereof to the periphery.